{"gene":"SLC5A2","run_date":"2026-06-10T07:46:34","timeline":{"discoveries":[{"year":2014,"finding":"SGLT2 (SLC5A2) mediates cellular uptake of aminoglycosides (gentamicin) in kidney proximal tubule cells. D-glucose competitively decreased gentamicin uptake, phlorizin (SGLT2 antagonist) inhibited uptake in a dose- and time-dependent manner, SGLT2 transfection of distal tubule cells enhanced gentamicin uptake, siRNA knockdown of SGLT2 reduced gentamicin-induced cytotoxicity, and phlorizin failed to inhibit uptake in Sglt2-null mice.","method":"Competitive uptake assay with fluorescent glucose analog, phlorizin inhibition, SGLT2 transfection of KDT3 cells, siRNA knockdown, Sglt2 knockout mice with in vivo GTTR uptake measurement","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (competitive inhibition, transfection gain-of-function, siRNA loss-of-function, genetic knockout in vivo) in a single focused study, all consistent","pmids":["25268124"],"is_preprint":false},{"year":2011,"finding":"SGLT2 deletion in mice causes a ~500-fold increase in glucosuria, demonstrating that SGLT2 is the dominant pathway for renal glucose reabsorption in the proximal tubule. Knockout mice were protected from high-fat diet-induced hyperglycemia and had preserved pancreatic β-cell function and increased β-cell mass.","method":"SGLT2 knockout mouse model; metabolic cages, glucose tolerance tests, euglycemic and hyperglycemic clamps, isolated islet and perifusion studies","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal physiological readouts (glucosuria, glucose tolerance, insulin clamp, β-cell mass), replicated across dietary and genetic diabetic backgrounds","pmids":["21357472"],"is_preprint":false},{"year":2005,"finding":"A homozygous missense mutation K321R in the eighth transmembrane domain of SGLT2 (SLC5A2) causes severe familial renal glucosuria, establishing that this domain is critical for normal glucose transport function.","method":"DNA sequencing of entire SLC5A2 coding region, PCR-RFLP confirmation, haplotype analysis in consanguineous families with familial renal glucosuria","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — human genetic loss-of-function (homozygous missense) with phenotypic segregation; no in vitro reconstitution of transport activity, but cosegregation confirmed in multiple family members","pmids":["15610225"],"is_preprint":false},{"year":2006,"finding":"Multiple novel loss-of-function mutations in SLC5A2 (including IVS12+1G>A, p.A102V homozygous, compound heterozygous p.R132H/p.A219T, and p.Q167fsX186 frameshift) cause familial renal glucosuria, and massive glucosuria from homozygous p.A102V is associated with renal sodium wasting and activation of the renin-angiotensin-aldosterone system, indicating that SGLT2-mediated glucose reabsorption is coupled to sodium reabsorption in vivo.","method":"SLC5A2 coding region sequencing, PCR amplification, phenotypic characterization including plasma renin and aldosterone measurement","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — human genetic loss-of-function with physiological phenotyping; multiple independent families but no in vitro transport reconstitution","pmids":["16518345"],"is_preprint":false},{"year":2018,"finding":"SGLT2 inhibition increases fractional renal urate excretion through a mechanism requiring URAT1 but not tubular GLUT9; increased luminal glucose delivery (as shown by additive effects of combined Sglt2/Sglt1 genetic ablation) contributes to the uricosuric effect. Pharmacological and genetic SGLT2 inhibition also upregulated renal Glut9 mRNA.","method":"Canagliflozin treatment in non-diabetic mice; gene-targeted Sglt2-KO, Sglt1-KO, Urat1-KO, and tubule-specific Glut9-KO mice; renal clearance studies with FITC-sinistrin for GFR; urate measurement in plasma and urine","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological and multiple genetic knockout models with mechanistic epistasis, multiple orthogonal measurements of urate handling","pmids":["30427222"],"is_preprint":false},{"year":2020,"finding":"SGLT2 is expressed in human pancreatic α-cells (but not β-cells or δ-cells), and inter-individual heterogeneity in SGLT2 protein expression correlates with variability in dapagliflozin-induced glucagon secretion; SGLT2 inhibition directly stimulates glucagon secretion from human islets in a glucose-dependent manner.","method":"RNA sequencing of 207 donors; rigorously validated anti-SGLT2 antibody; Western blot and immunofluorescence on islets from 10–12 donors; quantitative colocalization analysis of 665 human islets; glucagon secretion assays from 31 donors with dapagliflozin","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (RNA-seq, validated antibody, immunofluorescence, functional glucagon secretion) in a large human islet cohort","pmids":["31896553"],"is_preprint":false},{"year":2019,"finding":"SGLT2 is functionally expressed in human breast cancer MCF-7 cells and mediates glucose-induced whole-cell sodium current; ipragliflozin (SGLT2 inhibitor) suppressed MCF-7 proliferation in a dose-dependent manner, and this effect was completely abolished by SGLT2 knockdown, indicating on-target SGLT2-mediated action. SGLT2 inhibition also caused membrane hyperpolarization and mitochondrial membrane potential changes.","method":"RT-PCR, immunohistochemistry, BrdU proliferation assay, siRNA knockdown, patch-clamp electrophysiology (membrane potential and whole-cell current)","journal":"Endocrine journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown rescue experiment plus patch-clamp electrophysiology in single cell line; single lab","pmids":["31776304"],"is_preprint":false},{"year":2023,"finding":"SGLT2 inhibition with empagliflozin in human cardiomyocytes exposed to high glucose prevents TET2-mediated DNA demethylation at NF-κB and SOD2 promoters, reducing their aberrant gene expression. Transient SGLT2 gene silencing alone recapitulated the prevention of demethylation, establishing SGLT2 as required for high-glucose-induced epigenetic changes in cardiomyocytes.","method":"AC16 cardiomyocyte high-glucose model; pyrosequencing-based methylation analysis; siRNA SGLT2 silencing; chromatin immunoprecipitation-qPCR for TET2 occupancy; RT-qPCR and Western blot","journal":"Cardiovascular diabetology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR with siRNA rescue in human cardiomyocyte cell line; single lab, multiple orthogonal methods","pmids":["36732760"],"is_preprint":false},{"year":2022,"finding":"SGLT2 protein is expressed in human cardiomyocytes; expression is increased in diabetic versus non-diabetic failing hearts and is upregulated by high glucose in cultured AC16 human cardiomyocytes, as confirmed by immunofluorescence colocalization, Western blot, and RT-PCR.","method":"Immunohistochemistry, immunofluorescence, Western blot, RT-qPCR on explanted human hearts and endomyocardial biopsies; high-glucose treatment of AC16 cells","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple detection methods (IF, WB, PCR) in human tissue and cell line, but no functional transport assay in cardiomyocytes; single lab","pmids":["36096423"],"is_preprint":false},{"year":2023,"finding":"SGLT2 expression is increased and colocalizes with decreased synaptopodin in podocytes of lupus nephritis patients and MRL/lpr mice; CRISPR/Cas9-generated SGLT2 knockout podocyte cells show that SGLT2 mediates mTORC1 activity, and empagliflozin attenuates podocyte injury by reducing mTORC1 activity and enhancing autophagy.","method":"CRISPR/Cas9 SGLT2 knockout podocyte cell line; empagliflozin treatment of MRL/lpr mice; immunofluorescence colocalization; mTORC1 activity assays","journal":"Annals of the rheumatic diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR knockout cell line with mechanistic follow-up plus in vivo mouse model; single lab","pmids":["37487609"],"is_preprint":false},{"year":2023,"finding":"SGLT2 inhibitor treatment broadly downregulates the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acid transporters) in the proximal tubule; mouse and human SGLT2 interactome studies revealed binding partners consistent with this coordinated transport regulation.","method":"Proteomics, phosphoproteomics, metabolomics of kidneys/heart/liver/adipose in nondiabetic and diabetic mice after 1 week SGLT2i; SGLT2 interactome studies in mouse and human tissue","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-omic approach with interactome data; breadth of findings is strong but interactome details are not individually validated by orthogonal methods in the abstract","pmids":["38152989"],"is_preprint":false},{"year":2021,"finding":"SGLT2 is expressed at mRNA and protein levels in the proximal tubule; single-cell RNA sequencing of human kidney biopsies confirms SGLT2 expression exclusively in the proximal tubular cell cluster, and SGLT2 inhibitor treatment suppresses mTORC1 signaling across nephron segments, with decreased phospho-S6 protein in both proximal and distal tubules confirmed by immunostaining.","method":"Single-cell RNA sequencing of research kidney biopsies from youth-onset T2D patients and healthy controls; phospho-S6 immunostaining; comparison of SGLT2i-treated vs. untreated T2D patients","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — scRNA-seq plus protein-level validation (phospho-S6 IHC) in human biopsy samples; single study, no in vitro mechanistic reconstitution","pmids":["36637914"],"is_preprint":false},{"year":2023,"finding":"COVID-19 proinflammatory cytokines (IL-1β, IL-6, TNF-α) induce redox-sensitive SGLT2 upregulation in endothelial cells, which in turn drives endothelial dysfunction, senescence, NF-κB activation, platelet adhesion/aggregation, and thrombin generation; neutralizing antibodies against these cytokines and empagliflozin both blocked this pathway.","method":"Porcine coronary artery endothelial cells incubated with COVID-19 patient plasma; Western blot, immunofluorescence, RT-qPCR; dihydroethidium for oxidative stress; neutralizing antibody blockade; empagliflozin treatment; platelet adhesion/aggregation and thrombin generation assays","journal":"Journal of thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods with cytokine neutralization controls establishing pathway direction; single lab, ex vivo/in vitro model","pmids":["37797691"],"is_preprint":false},{"year":2019,"finding":"A novel compound heterozygous mutation (p.W172R; p.P514S) in SLC5A2 is associated with familial renal glucosuria, extending the catalog of loss-of-function mutations that disrupt SGLT2-mediated glucose reabsorption.","method":"SLC5A2 gene sequencing; in silico functional prediction tools; literature review of 86 SLC5A2 mutations","journal":"Molecular medicine reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — human genetic association with phenotype, no in vitro transport reconstitution or functional validation of the specific mutations","pmids":["30942416"],"is_preprint":false},{"year":2024,"finding":"SGLT2 inhibitor dapagliflozin targets estrogen-related receptor α (ERRα), activating the ERRα–OAT1 axis to enhance uric acid excretion and reduce tubulointerstitial fibrosis in hyperuricemic nephropathy; dual-luciferase reporter assays confirmed transcription factor binding, and ERRα knockin mice showed UA resistance.","method":"Transcriptomic analysis of patients and HN mice; HK-2 cell UA stimulation; ERRα knockin mice; ERRα-overexpressed HK-2 cells; dual-luciferase reporter assay; ERRα inhibition; dapagliflozin treatment in vivo and in vitro","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomics plus gain/loss-of-function genetics plus luciferase reporter; single lab, novel pathway identification","pmids":["39168099"],"is_preprint":false},{"year":2024,"finding":"MicroRNA-296-5p directly targets and downregulates SGLT2 in lung cancer cells; siRNA knockdown of SGLT2 inhibited cell proliferation and impeded cell cycle progression, establishing SGLT2 as functionally required for lung cancer cell growth.","method":"RT-qPCR and Western blot in human lung cancer samples and cell lines; miR-296-5p overexpression; siRNA SGLT2 knockdown; proliferation and cell cycle assays","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — siRNA knockdown with functional readout plus miRNA targeting experiment; single lab","pmids":["30365049"],"is_preprint":false}],"current_model":"SLC5A2/SGLT2 is an electrogenic sodium-glucose cotransporter expressed predominantly in the S1 segment of the renal proximal tubule, where it mediates the majority of filtered glucose reabsorption coupled to sodium transport; loss-of-function mutations in SLC5A2 cause familial renal glucosuria, and genetic deletion in mice produces massive glucosuria with preserved β-cell function; beyond the kidney, SGLT2 is functionally expressed in pancreatic α-cells (where it regulates glucagon secretion), in cardiomyocytes (where its expression is upregulated by high glucose), in certain cancer cells (where it mediates glucose uptake supporting proliferation), and in endothelial cells (where proinflammatory cytokines upregulate it to drive dysfunction); SGLT2 also traffics aminoglycosides in proximal tubule cells and, through interactome studies, coordinates a broad apical transport complex; pharmacological SGLT2 inhibition suppresses mTORC1 signaling, modulates epigenetic marks via TET2, influences urate excretion through a URAT1-dependent luminal glucose mechanism, and activates ERRα–OAT1 signaling, collectively contributing to renal and cardiovascular protection."},"narrative":{"mechanistic_narrative":"SLC5A2 (SGLT2) is the dominant electrogenic sodium-coupled glucose cotransporter of the renal proximal tubule, where it carries out the bulk of filtered glucose reabsorption: genetic deletion in mice produces ~500-fold glucosuria with preserved pancreatic β-cell function [PMID:21357472], and single-cell profiling localizes its expression exclusively to the proximal tubular cell cluster [PMID:36637914]. Loss-of-function mutations across the SLC5A2 coding sequence cause familial renal glucosuria, with the K321R substitution in the eighth transmembrane domain marking a region critical for transport and homozygous lesions producing massive glucosuria accompanied by renal sodium wasting and renin-angiotensin-aldosterone activation, confirming that glucose reabsorption is sodium-coupled in vivo [PMID:15610225, PMID:16518345]. Beyond glucose, SGLT2 transports aminoglycosides into proximal tubule cells, accounting for their cellular uptake and cytotoxicity [PMID:25268124], and it coordinates a broad apical uptake transport network whose components are downregulated upon SGLT2 inhibition [PMID:38152989]. Pharmacological SGLT2 blockade enhances fractional urate excretion through a URAT1-dependent luminal-glucose mechanism [PMID:30427222] and via activation of an ERRα–OAT1 axis [PMID:39168099], and suppresses mTORC1 signaling across nephron segments [PMID:36637914]. Outside the kidney, SGLT2 is functionally expressed in pancreatic α-cells where its inhibition stimulates glucose-dependent glucagon secretion [PMID:31896553], in cardiomyocytes where high glucose upregulates it and drives TET2-mediated promoter demethylation of NF-κB and SOD2 [PMID:36732760, PMID:36096423], in cytokine-stimulated endothelial cells where it propagates dysfunction and thrombotic signaling [PMID:37797691], and in breast and lung cancer cells where it supports proliferation [PMID:31776304, PMID:30365049].","teleology":[{"year":2005,"claim":"Establishing which protein regions are essential for human glucose transport, a homozygous missense mutation pinpointed the eighth transmembrane domain as critical for SGLT2 function.","evidence":"SLC5A2 coding sequencing and haplotype analysis in consanguineous familial renal glucosuria families","pmids":["15610225"],"confidence":"Medium","gaps":["No in vitro reconstitution of the K321R transport defect","Does not quantify residual transport activity"]},{"year":2006,"claim":"By characterizing multiple loss-of-function alleles together with their physiological phenotypes, this work demonstrated that SGLT2-mediated glucose reabsorption is coupled to sodium reabsorption in vivo.","evidence":"SLC5A2 sequencing plus plasma renin/aldosterone phenotyping in familial renal glucosuria families","pmids":["16518345"],"confidence":"Medium","gaps":["No in vitro transport reconstitution of the mutant alleles","Sodium coupling inferred from RAAS activation rather than direct flux measurement"]},{"year":2011,"claim":"Whether SGLT2 is the principal renal glucose-reabsorption pathway and whether its loss is metabolically tolerated was resolved by genetic deletion, which caused massive glucosuria yet preserved β-cell function.","evidence":"SGLT2 knockout mouse with metabolic cages, glucose tolerance tests, clamps, and islet perifusion","pmids":["21357472"],"confidence":"High","gaps":["Does not address extrarenal SGLT2 functions","Mechanism of β-cell mass increase not defined"]},{"year":2014,"claim":"Beyond glucose, SGLT2 was shown to be a route for proximal tubule uptake of aminoglycosides, explaining a cellular basis for their nephrotoxicity.","evidence":"Competitive uptake assays, phlorizin inhibition, transfection gain-of-function, siRNA knockdown, and Sglt2-null mice","pmids":["25268124"],"confidence":"High","gaps":["Transport stoichiometry for aminoglycosides not determined","Generalizability to other aminoglycosides beyond gentamicin not tested"]},{"year":2018,"claim":"The mechanism by which SGLT2 inhibition affects urate handling was mapped to luminal glucose delivery acting through URAT1 rather than tubular GLUT9.","evidence":"Canagliflozin treatment plus Sglt2-, Sglt1-, Urat1-, and tubule-specific Glut9-knockout mice with renal clearance studies","pmids":["30427222"],"confidence":"High","gaps":["Molecular link between luminal glucose and URAT1 activity not resolved","Human relevance not directly tested"]},{"year":2019,"claim":"Extending SGLT2 function beyond kidney, expression and inhibitor-sensitive proliferation were demonstrated in breast cancer cells, implicating SGLT2 in supporting tumor cell growth.","evidence":"RT-PCR, IHC, BrdU assay, siRNA knockdown rescue, and patch-clamp in MCF-7 cells","pmids":["31776304"],"confidence":"Medium","gaps":["Single cell line, single lab","In vivo tumor relevance not established"]},{"year":2020,"claim":"The basis for SGLT2-inhibitor effects on glucagon was established by localizing SGLT2 to pancreatic α-cells and linking expression heterogeneity to glucagon-secretion responses.","evidence":"RNA-seq of 207 donors, validated antibody immunofluorescence, and glucagon secretion assays from human islets","pmids":["31896553"],"confidence":"High","gaps":["Transport mechanism within α-cells not defined","Signaling pathway from SGLT2 to glucagon release not resolved"]},{"year":2022,"claim":"Whether SGLT2 is expressed in human heart was addressed by detecting it in cardiomyocytes with upregulation in diabetic failing hearts and by high glucose.","evidence":"IHC, immunofluorescence, Western blot, and RT-qPCR on human hearts and AC16 cardiomyocytes","pmids":["36096423"],"confidence":"Medium","gaps":["No functional glucose transport assay in cardiomyocytes","Single lab"]},{"year":2023,"claim":"Connecting renal SGLT2 to a growth/stress signaling node, inhibition was shown to suppress mTORC1 signaling across nephron segments.","evidence":"scRNA-seq of human kidney biopsies plus phospho-S6 immunostaining in SGLT2i-treated versus untreated T2D patients","pmids":["36637914"],"confidence":"Medium","gaps":["Direct mechanistic link from transport activity to mTORC1 not reconstituted","Distal-tubule effect (lacking SGLT2) implies indirect mechanism"]},{"year":2023,"claim":"A cardiac epigenetic role was defined by showing SGLT2 is required for high-glucose-induced TET2-mediated demethylation of NF-κB and SOD2 promoters.","evidence":"AC16 high-glucose model with siRNA silencing, pyrosequencing methylation, and ChIP-qPCR for TET2","pmids":["36732760"],"confidence":"Medium","gaps":["Mechanism linking SGLT2 transport to TET2 recruitment unknown","Single cell line"]},{"year":2023,"claim":"An endothelial inflammatory circuit was established in which proinflammatory cytokines drive redox-sensitive SGLT2 upregulation that propagates endothelial dysfunction and thrombotic signaling.","evidence":"Porcine coronary endothelial cells with COVID-19 plasma, cytokine neutralization, empagliflozin, and platelet/thrombin assays","pmids":["37797691"],"confidence":"Medium","gaps":["Direct transport function in endothelium not measured","Ex vivo/in vitro model only"]},{"year":2023,"claim":"A podocyte role was demonstrated by showing SGLT2 mediates mTORC1 activity and that its inhibition attenuates podocyte injury in lupus nephritis.","evidence":"CRISPR/Cas9 SGLT2-knockout podocyte line plus empagliflozin in MRL/lpr mice with mTORC1 assays","pmids":["37487609"],"confidence":"Medium","gaps":["Single lab","Coupling between glucose transport and mTORC1 in podocytes not mechanistically defined"]},{"year":2023,"claim":"Multi-omic profiling revealed that SGLT2 inhibition broadly downregulates the proximal-tubule apical transport machinery and identified an SGLT2 interactome consistent with coordinated transport regulation.","evidence":"Proteomics, phosphoproteomics, metabolomics, and SGLT2 interactome studies in mouse and human tissue","pmids":["38152989"],"confidence":"Medium","gaps":["Individual interactome partners not orthogonally validated","Direct versus indirect transporter downregulation not distinguished"]},{"year":2024,"claim":"A transcriptional target was identified by showing dapagliflozin activates an ERRα–OAT1 axis to enhance urate excretion and reduce fibrosis.","evidence":"Transcriptomics, ERRα knockin mice, ERRα-overexpressing HK-2 cells, and dual-luciferase reporter assays","pmids":["39168099"],"confidence":"Medium","gaps":["Whether ERRα effect is independent of glucose transport unclear","Single lab"]},{"year":2024,"claim":"Lung cancer dependency was established by showing miR-296-5p represses SGLT2 and that SGLT2 is functionally required for proliferation and cell-cycle progression.","evidence":"RT-qPCR/Western blot in lung cancer samples, miR-296-5p overexpression, siRNA knockdown, and proliferation/cell-cycle assays","pmids":["30365049"],"confidence":"Medium","gaps":["In vivo tumor relevance not tested","Single lab"]},{"year":null,"claim":"How SGLT2 transport activity is mechanistically coupled to its extrarenal signaling effects (mTORC1 suppression, TET2-dependent demethylation, ERRα activation) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking transport to signaling outputs","Direct versus inhibitor-pleiotropic mechanisms not separated","Interactome partners not individually validated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,1,6]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,11]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,1,4]}],"complexes":[],"partners":["URAT1","SLC2A9","ESRRA","OAT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P31639","full_name":"Sodium/glucose cotransporter 2","aliases":["Low affinity sodium-glucose cotransporter","Solute carrier family 5 member 2"],"length_aa":672,"mass_kda":72.9,"function":"Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose at the plasma membrane, with a Na(+) to sugar coupling ratio of 1:1 (PubMed:20980548, PubMed:28592437, PubMed:34880493, PubMed:37217492, PubMed:38057552). Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump (PubMed:20980548, PubMed:28592437, PubMed:34880493). Unlike SLC5A1/SGLT1, requires the auxiliary protein PDZK1IP1/MAP17 for full transporter activity (PubMed:37217492). Has a primary role in D-glucose reabsorption from glomerular filtrate across the brush border of the early proximal tubules of the kidney (By similarity)","subcellular_location":"Apical cell membrane","url":"https://www.uniprot.org/uniprotkb/P31639/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC5A2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLC5A2","total_profiled":1310},"omim":[{"mim_id":"620216","title":"SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 9; SLC5A9","url":"https://www.omim.org/entry/620216"},{"mim_id":"612541","title":"NEUTROPENIA, SEVERE CONGENITAL, 4, AUTOSOMAL RECESSIVE; SCN4","url":"https://www.omim.org/entry/612541"},{"mim_id":"612018","title":"CATARACT 47; CTRCT47","url":"https://www.omim.org/entry/612018"},{"mim_id":"611910","title":"SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 12; SLC16A12","url":"https://www.omim.org/entry/611910"},{"mim_id":"233100","title":"RENAL GLUCOSURIA; GLYS","url":"https://www.omim.org/entry/233100"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"kidney","ntpm":52.2}],"url":"https://www.proteinatlas.org/search/SLC5A2"},"hgnc":{"alias_symbol":[],"prev_symbol":["SGLT2"]},"alphafold":{"accession":"P31639","domains":[{"cath_id":"1.20.1730.10","chopping":"24-266_296-453_645-672","consensus_level":"high","plddt":88.5457,"start":24,"end":672}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P31639","model_url":"https://alphafold.ebi.ac.uk/files/AF-P31639-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P31639-F1-predicted_aligned_error_v6.png","plddt_mean":83.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC5A2","jax_strain_url":"https://www.jax.org/strain/search?query=SLC5A2"},"sequence":{"accession":"P31639","fasta_url":"https://rest.uniprot.org/uniprotkb/P31639.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P31639/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P31639"}},"corpus_meta":[{"pmid":"30710997","id":"PMC_30710997","title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.","date":"2019","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/30710997","citation_count":482,"is_preprint":false},{"pmid":"34216571","id":"PMC_34216571","title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.","date":"2021","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34216571","citation_count":439,"is_preprint":false},{"pmid":"22310849","id":"PMC_22310849","title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.","date":"2012","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22310849","citation_count":363,"is_preprint":false},{"pmid":"36315602","id":"PMC_36315602","title":"Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/36315602","citation_count":336,"is_preprint":false},{"pmid":"25616707","id":"PMC_25616707","title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.","date":"2015","source":"Diabetes & vascular disease research","url":"https://pubmed.ncbi.nlm.nih.gov/25616707","citation_count":312,"is_preprint":false},{"pmid":"32726607","id":"PMC_32726607","title":"SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.","date":"2020","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32726607","citation_count":307,"is_preprint":false},{"pmid":"30132033","id":"PMC_30132033","title":"Development of SGLT1 and SGLT2 inhibitors.","date":"2018","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/30132033","citation_count":277,"is_preprint":false},{"pmid":"25341005","id":"PMC_25341005","title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.","date":"2014","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25341005","citation_count":263,"is_preprint":false},{"pmid":"34885795","id":"PMC_34885795","title":"Neuroprotective Effect of SGLT2 Inhibitors.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34885795","citation_count":233,"is_preprint":false},{"pmid":"31426529","id":"PMC_31426529","title":"SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.","date":"2019","source":"International journal of environmental research and public health","url":"https://pubmed.ncbi.nlm.nih.gov/31426529","citation_count":199,"is_preprint":false},{"pmid":"21357472","id":"PMC_21357472","title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.","date":"2011","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/21357472","citation_count":185,"is_preprint":false},{"pmid":"35812300","id":"PMC_35812300","title":"Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.","date":"2022","source":"Kidney international reports","url":"https://pubmed.ncbi.nlm.nih.gov/35812300","citation_count":166,"is_preprint":false},{"pmid":"28432726","id":"PMC_28432726","title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.","date":"2017","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28432726","citation_count":153,"is_preprint":false},{"pmid":"27391020","id":"PMC_27391020","title":"Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27391020","citation_count":147,"is_preprint":false},{"pmid":"33417139","id":"PMC_33417139","title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.","date":"2021","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/33417139","citation_count":143,"is_preprint":false},{"pmid":"30427222","id":"PMC_30427222","title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.","date":"2018","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30427222","citation_count":140,"is_preprint":false},{"pmid":"21358698","id":"PMC_21358698","title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.","date":"2011","source":"Kidney international. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/21358698","citation_count":139,"is_preprint":false},{"pmid":"38152989","id":"PMC_38152989","title":"Metabolic Communication by SGLT2 Inhibition.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/38152989","citation_count":120,"is_preprint":false},{"pmid":"38456601","id":"PMC_38456601","title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.","date":"2024","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/38456601","citation_count":115,"is_preprint":false},{"pmid":"38816549","id":"PMC_38816549","title":"SGLT2 inhibition eliminates senescent cells and alleviates pathological aging.","date":"2024","source":"Nature aging","url":"https://pubmed.ncbi.nlm.nih.gov/38816549","citation_count":100,"is_preprint":false},{"pmid":"36637914","id":"PMC_36637914","title":"SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36637914","citation_count":98,"is_preprint":false},{"pmid":"36096423","id":"PMC_36096423","title":"Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/36096423","citation_count":92,"is_preprint":false},{"pmid":"37487609","id":"PMC_37487609","title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy.","date":"2023","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37487609","citation_count":89,"is_preprint":false},{"pmid":"29485006","id":"PMC_29485006","title":"Risks Associated with SGLT2 Inhibitors: An Overview.","date":"2018","source":"Current drug safety","url":"https://pubmed.ncbi.nlm.nih.gov/29485006","citation_count":89,"is_preprint":false},{"pmid":"38118414","id":"PMC_38118414","title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2.","date":"2023","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38118414","citation_count":82,"is_preprint":false},{"pmid":"34846711","id":"PMC_34846711","title":"Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.","date":"2021","source":"Advances in therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34846711","citation_count":82,"is_preprint":false},{"pmid":"33274396","id":"PMC_33274396","title":"SGLT2-inhibitors; more than just glycosuria and diuresis.","date":"2020","source":"Heart failure reviews","url":"https://pubmed.ncbi.nlm.nih.gov/33274396","citation_count":80,"is_preprint":false},{"pmid":"36161993","id":"PMC_36161993","title":"SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.","date":"2022","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/36161993","citation_count":75,"is_preprint":false},{"pmid":"15610225","id":"PMC_15610225","title":"A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria.","date":"2005","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/15610225","citation_count":75,"is_preprint":false},{"pmid":"32327107","id":"PMC_32327107","title":"Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.","date":"2020","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/32327107","citation_count":75,"is_preprint":false},{"pmid":"31776304","id":"PMC_31776304","title":"SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.","date":"2019","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/31776304","citation_count":72,"is_preprint":false},{"pmid":"16518345","id":"PMC_16518345","title":"Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16518345","citation_count":71,"is_preprint":false},{"pmid":"37055837","id":"PMC_37055837","title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms.","date":"2023","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/37055837","citation_count":70,"is_preprint":false},{"pmid":"37509506","id":"PMC_37509506","title":"SGLT2 Inhibitors as Potential Anticancer Agents.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/37509506","citation_count":70,"is_preprint":false},{"pmid":"34918381","id":"PMC_34918381","title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34918381","citation_count":66,"is_preprint":false},{"pmid":"36765176","id":"PMC_36765176","title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival.","date":"2023","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36765176","citation_count":65,"is_preprint":false},{"pmid":"22381403","id":"PMC_22381403","title":"Effects of SGLT2 inhibitors on cardiovascular outcomes.","date":"2012","source":"Diabetes & vascular disease research","url":"https://pubmed.ncbi.nlm.nih.gov/22381403","citation_count":61,"is_preprint":false},{"pmid":"38199714","id":"PMC_38199714","title":"Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week.","date":"2024","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/38199714","citation_count":60,"is_preprint":false},{"pmid":"36396554","id":"PMC_36396554","title":"Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure.","date":"2022","source":"JACC. Heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/36396554","citation_count":60,"is_preprint":false},{"pmid":"35862082","id":"PMC_35862082","title":"Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/35862082","citation_count":55,"is_preprint":false},{"pmid":"37047011","id":"PMC_37047011","title":"Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37047011","citation_count":54,"is_preprint":false},{"pmid":"37848934","id":"PMC_37848934","title":"SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.","date":"2023","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/37848934","citation_count":53,"is_preprint":false},{"pmid":"26513131","id":"PMC_26513131","title":"SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.","date":"2015","source":"Expert opinion on drug safety","url":"https://pubmed.ncbi.nlm.nih.gov/26513131","citation_count":53,"is_preprint":false},{"pmid":"37623335","id":"PMC_37623335","title":"SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.","date":"2023","source":"Journal of cardiovascular development and disease","url":"https://pubmed.ncbi.nlm.nih.gov/37623335","citation_count":53,"is_preprint":false},{"pmid":"37428955","id":"PMC_37428955","title":"Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.","date":"2023","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/37428955","citation_count":51,"is_preprint":false},{"pmid":"39243758","id":"PMC_39243758","title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation.","date":"2024","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39243758","citation_count":48,"is_preprint":false},{"pmid":"36696485","id":"PMC_36696485","title":"SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36696485","citation_count":48,"is_preprint":false},{"pmid":"40004134","id":"PMC_40004134","title":"Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40004134","citation_count":47,"is_preprint":false},{"pmid":"39340828","id":"PMC_39340828","title":"Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/39340828","citation_count":45,"is_preprint":false},{"pmid":"39294445","id":"PMC_39294445","title":"SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization.","date":"2024","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/39294445","citation_count":44,"is_preprint":false},{"pmid":"25268124","id":"PMC_25268124","title":"Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25268124","citation_count":43,"is_preprint":false},{"pmid":"35053290","id":"PMC_35053290","title":"Antioxidant Roles of SGLT2 Inhibitors in the Kidney.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35053290","citation_count":43,"is_preprint":false},{"pmid":"31896553","id":"PMC_31896553","title":"Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.","date":"2020","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/31896553","citation_count":43,"is_preprint":false},{"pmid":"26362302","id":"PMC_26362302","title":"SGLT2 inhibitors.","date":"2015","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26362302","citation_count":41,"is_preprint":false},{"pmid":"39168099","id":"PMC_39168099","title":"The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39168099","citation_count":39,"is_preprint":false},{"pmid":"38170280","id":"PMC_38170280","title":"Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes.","date":"2024","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/38170280","citation_count":39,"is_preprint":false},{"pmid":"28203358","id":"PMC_28203358","title":"The renal effects of SGLT2 inhibitors and a mini-review of the literature.","date":"2016","source":"Therapeutic advances in endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28203358","citation_count":39,"is_preprint":false},{"pmid":"36732760","id":"PMC_36732760","title":"Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors.","date":"2023","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/36732760","citation_count":39,"is_preprint":false},{"pmid":"38770818","id":"PMC_38770818","title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.","date":"2024","source":"The Cochrane database of systematic reviews","url":"https://pubmed.ncbi.nlm.nih.gov/38770818","citation_count":38,"is_preprint":false},{"pmid":"28482281","id":"PMC_28482281","title":"ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease.","date":"2017","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28482281","citation_count":38,"is_preprint":false},{"pmid":"38492622","id":"PMC_38492622","title":"Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement.","date":"2024","source":"Current problems in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/38492622","citation_count":38,"is_preprint":false},{"pmid":"39046464","id":"PMC_39046464","title":"Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.","date":"2024","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/39046464","citation_count":37,"is_preprint":false},{"pmid":"37069192","id":"PMC_37069192","title":"SGLT2 inhibition ameliorates nano plastics-induced premature endothelial senescence and dysfunction.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37069192","citation_count":36,"is_preprint":false},{"pmid":"34341711","id":"PMC_34341711","title":"The Role of SGLT2 Inhibitors in Vascular Aging.","date":"2021","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/34341711","citation_count":36,"is_preprint":false},{"pmid":"28134748","id":"PMC_28134748","title":"Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.","date":"2017","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/28134748","citation_count":35,"is_preprint":false},{"pmid":"30017776","id":"PMC_30017776","title":"SGLT2 inhibition and glucagon secretion in humans.","date":"2018","source":"Diabetes & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30017776","citation_count":34,"is_preprint":false},{"pmid":"37500266","id":"PMC_37500266","title":"The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond.","date":"2023","source":"European heart journal. Cardiovascular pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/37500266","citation_count":34,"is_preprint":false},{"pmid":"27440828","id":"PMC_27440828","title":"Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.","date":"2016","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/27440828","citation_count":34,"is_preprint":false},{"pmid":"36589841","id":"PMC_36589841","title":"Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36589841","citation_count":33,"is_preprint":false},{"pmid":"37242177","id":"PMC_37242177","title":"SGLT-2 Inhibitors and the Inflammasome: What's Next in the 21st Century?","date":"2023","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/37242177","citation_count":32,"is_preprint":false},{"pmid":"38269506","id":"PMC_38269506","title":"SGLT2 inhibitors and AMPK: The road to cellular housekeeping?","date":"2024","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/38269506","citation_count":30,"is_preprint":false},{"pmid":"29334278","id":"PMC_29334278","title":"A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment.","date":"2018","source":"Expert opinion on drug safety","url":"https://pubmed.ncbi.nlm.nih.gov/29334278","citation_count":30,"is_preprint":false},{"pmid":"38488029","id":"PMC_38488029","title":"Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review).","date":"2024","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/38488029","citation_count":27,"is_preprint":false},{"pmid":"38523292","id":"PMC_38523292","title":"SGLT2 inhibition and three urological cancers: Up-to-date results.","date":"2024","source":"Diabetes/metabolism research and reviews","url":"https://pubmed.ncbi.nlm.nih.gov/38523292","citation_count":26,"is_preprint":false},{"pmid":"34781282","id":"PMC_34781282","title":"Peritoneal Expression of SGLT-2, GLUT1, and GLUT3 in Peritoneal Dialysis Patients.","date":"2021","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/34781282","citation_count":26,"is_preprint":false},{"pmid":"38811901","id":"PMC_38811901","title":"SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.","date":"2024","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/38811901","citation_count":25,"is_preprint":false},{"pmid":"37797691","id":"PMC_37797691","title":"COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines/SGLT2 prooxidant pathway.","date":"2023","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/37797691","citation_count":25,"is_preprint":false},{"pmid":"26654860","id":"PMC_26654860","title":"The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.","date":"2015","source":"Canadian journal of diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26654860","citation_count":20,"is_preprint":false},{"pmid":"30365049","id":"PMC_30365049","title":"MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30365049","citation_count":20,"is_preprint":false},{"pmid":"38954371","id":"PMC_38954371","title":"SGLT2 inhibitor use in the management of feline diabetes mellitus.","date":"2024","source":"Journal of veterinary pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38954371","citation_count":19,"is_preprint":false},{"pmid":"30942416","id":"PMC_30942416","title":"A novel compound heterozygous mutation in SLC5A2 contributes to familial renal glucosuria in a Chinese family, and a review of the relevant literature.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30942416","citation_count":19,"is_preprint":false},{"pmid":"35235172","id":"PMC_35235172","title":"Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.","date":"2022","source":"Current hypertension reports","url":"https://pubmed.ncbi.nlm.nih.gov/35235172","citation_count":19,"is_preprint":false},{"pmid":"40868177","id":"PMC_40868177","title":"SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/40868177","citation_count":18,"is_preprint":false},{"pmid":"27709509","id":"PMC_27709509","title":"Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.","date":"2016","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/27709509","citation_count":18,"is_preprint":false},{"pmid":"39633372","id":"PMC_39633372","title":"SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes.","date":"2024","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/39633372","citation_count":17,"is_preprint":false},{"pmid":"40348751","id":"PMC_40348751","title":"SGLT2 inhibitors as a novel senotherapeutic approach.","date":"2025","source":"npj aging","url":"https://pubmed.ncbi.nlm.nih.gov/40348751","citation_count":17,"is_preprint":false},{"pmid":"37126209","id":"PMC_37126209","title":"The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy.","date":"2023","source":"Journal of cardiovascular translational research","url":"https://pubmed.ncbi.nlm.nih.gov/37126209","citation_count":17,"is_preprint":false},{"pmid":"37910600","id":"PMC_37910600","title":"The SGLT2 inhibitor dapagliflozin improves kidney function in glycogen storage disease XI.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37910600","citation_count":16,"is_preprint":false},{"pmid":"38803397","id":"PMC_38803397","title":"SGLT2 inhibition to target kidney aging.","date":"2024","source":"Clinical kidney journal","url":"https://pubmed.ncbi.nlm.nih.gov/38803397","citation_count":16,"is_preprint":false},{"pmid":"40237854","id":"PMC_40237854","title":"SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2.","date":"2025","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/40237854","citation_count":15,"is_preprint":false},{"pmid":"37927142","id":"PMC_37927142","title":"SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma.","date":"2023","source":"Journal of hepato-biliary-pancreatic sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37927142","citation_count":15,"is_preprint":false},{"pmid":"40796776","id":"PMC_40796776","title":"A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40796776","citation_count":15,"is_preprint":false},{"pmid":"40053507","id":"PMC_40053507","title":"SGLT2 inhibitors in CKD: are they really effective in all patients?","date":"2025","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/40053507","citation_count":14,"is_preprint":false},{"pmid":"38031729","id":"PMC_38031729","title":"SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy.","date":"2023","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/38031729","citation_count":14,"is_preprint":false},{"pmid":"39013942","id":"PMC_39013942","title":"SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39013942","citation_count":14,"is_preprint":false},{"pmid":"39457625","id":"PMC_39457625","title":"Multifaceted Impact of SGLT2 Inhibitors in Heart Failure Patients: Exploring Diverse Mechanisms of Action.","date":"2024","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/39457625","citation_count":14,"is_preprint":false},{"pmid":"38611003","id":"PMC_38611003","title":"Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38611003","citation_count":14,"is_preprint":false},{"pmid":"37792168","id":"PMC_37792168","title":"The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy.","date":"2023","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37792168","citation_count":14,"is_preprint":false},{"pmid":"35077036","id":"PMC_35077036","title":"SGLT2 inhibitors in non-diabetic kidney disease.","date":"2022","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/35077036","citation_count":13,"is_preprint":false},{"pmid":"39510041","id":"PMC_39510041","title":"Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials.","date":"2024","source":"American journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/39510041","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53582,"output_tokens":4551,"usd":0.114505,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12707,"output_tokens":4334,"usd":0.085943,"stage2_stop_reason":"end_turn"},"total_usd":0.200448,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"SGLT2 (SLC5A2) mediates cellular uptake of aminoglycosides (gentamicin) in kidney proximal tubule cells. D-glucose competitively decreased gentamicin uptake, phlorizin (SGLT2 antagonist) inhibited uptake in a dose- and time-dependent manner, SGLT2 transfection of distal tubule cells enhanced gentamicin uptake, siRNA knockdown of SGLT2 reduced gentamicin-induced cytotoxicity, and phlorizin failed to inhibit uptake in Sglt2-null mice.\",\n      \"method\": \"Competitive uptake assay with fluorescent glucose analog, phlorizin inhibition, SGLT2 transfection of KDT3 cells, siRNA knockdown, Sglt2 knockout mice with in vivo GTTR uptake measurement\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (competitive inhibition, transfection gain-of-function, siRNA loss-of-function, genetic knockout in vivo) in a single focused study, all consistent\",\n      \"pmids\": [\"25268124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SGLT2 deletion in mice causes a ~500-fold increase in glucosuria, demonstrating that SGLT2 is the dominant pathway for renal glucose reabsorption in the proximal tubule. Knockout mice were protected from high-fat diet-induced hyperglycemia and had preserved pancreatic β-cell function and increased β-cell mass.\",\n      \"method\": \"SGLT2 knockout mouse model; metabolic cages, glucose tolerance tests, euglycemic and hyperglycemic clamps, isolated islet and perifusion studies\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal physiological readouts (glucosuria, glucose tolerance, insulin clamp, β-cell mass), replicated across dietary and genetic diabetic backgrounds\",\n      \"pmids\": [\"21357472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A homozygous missense mutation K321R in the eighth transmembrane domain of SGLT2 (SLC5A2) causes severe familial renal glucosuria, establishing that this domain is critical for normal glucose transport function.\",\n      \"method\": \"DNA sequencing of entire SLC5A2 coding region, PCR-RFLP confirmation, haplotype analysis in consanguineous families with familial renal glucosuria\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — human genetic loss-of-function (homozygous missense) with phenotypic segregation; no in vitro reconstitution of transport activity, but cosegregation confirmed in multiple family members\",\n      \"pmids\": [\"15610225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Multiple novel loss-of-function mutations in SLC5A2 (including IVS12+1G>A, p.A102V homozygous, compound heterozygous p.R132H/p.A219T, and p.Q167fsX186 frameshift) cause familial renal glucosuria, and massive glucosuria from homozygous p.A102V is associated with renal sodium wasting and activation of the renin-angiotensin-aldosterone system, indicating that SGLT2-mediated glucose reabsorption is coupled to sodium reabsorption in vivo.\",\n      \"method\": \"SLC5A2 coding region sequencing, PCR amplification, phenotypic characterization including plasma renin and aldosterone measurement\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — human genetic loss-of-function with physiological phenotyping; multiple independent families but no in vitro transport reconstitution\",\n      \"pmids\": [\"16518345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SGLT2 inhibition increases fractional renal urate excretion through a mechanism requiring URAT1 but not tubular GLUT9; increased luminal glucose delivery (as shown by additive effects of combined Sglt2/Sglt1 genetic ablation) contributes to the uricosuric effect. Pharmacological and genetic SGLT2 inhibition also upregulated renal Glut9 mRNA.\",\n      \"method\": \"Canagliflozin treatment in non-diabetic mice; gene-targeted Sglt2-KO, Sglt1-KO, Urat1-KO, and tubule-specific Glut9-KO mice; renal clearance studies with FITC-sinistrin for GFR; urate measurement in plasma and urine\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological and multiple genetic knockout models with mechanistic epistasis, multiple orthogonal measurements of urate handling\",\n      \"pmids\": [\"30427222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SGLT2 is expressed in human pancreatic α-cells (but not β-cells or δ-cells), and inter-individual heterogeneity in SGLT2 protein expression correlates with variability in dapagliflozin-induced glucagon secretion; SGLT2 inhibition directly stimulates glucagon secretion from human islets in a glucose-dependent manner.\",\n      \"method\": \"RNA sequencing of 207 donors; rigorously validated anti-SGLT2 antibody; Western blot and immunofluorescence on islets from 10–12 donors; quantitative colocalization analysis of 665 human islets; glucagon secretion assays from 31 donors with dapagliflozin\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (RNA-seq, validated antibody, immunofluorescence, functional glucagon secretion) in a large human islet cohort\",\n      \"pmids\": [\"31896553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SGLT2 is functionally expressed in human breast cancer MCF-7 cells and mediates glucose-induced whole-cell sodium current; ipragliflozin (SGLT2 inhibitor) suppressed MCF-7 proliferation in a dose-dependent manner, and this effect was completely abolished by SGLT2 knockdown, indicating on-target SGLT2-mediated action. SGLT2 inhibition also caused membrane hyperpolarization and mitochondrial membrane potential changes.\",\n      \"method\": \"RT-PCR, immunohistochemistry, BrdU proliferation assay, siRNA knockdown, patch-clamp electrophysiology (membrane potential and whole-cell current)\",\n      \"journal\": \"Endocrine journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown rescue experiment plus patch-clamp electrophysiology in single cell line; single lab\",\n      \"pmids\": [\"31776304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SGLT2 inhibition with empagliflozin in human cardiomyocytes exposed to high glucose prevents TET2-mediated DNA demethylation at NF-κB and SOD2 promoters, reducing their aberrant gene expression. Transient SGLT2 gene silencing alone recapitulated the prevention of demethylation, establishing SGLT2 as required for high-glucose-induced epigenetic changes in cardiomyocytes.\",\n      \"method\": \"AC16 cardiomyocyte high-glucose model; pyrosequencing-based methylation analysis; siRNA SGLT2 silencing; chromatin immunoprecipitation-qPCR for TET2 occupancy; RT-qPCR and Western blot\",\n      \"journal\": \"Cardiovascular diabetology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR with siRNA rescue in human cardiomyocyte cell line; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36732760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SGLT2 protein is expressed in human cardiomyocytes; expression is increased in diabetic versus non-diabetic failing hearts and is upregulated by high glucose in cultured AC16 human cardiomyocytes, as confirmed by immunofluorescence colocalization, Western blot, and RT-PCR.\",\n      \"method\": \"Immunohistochemistry, immunofluorescence, Western blot, RT-qPCR on explanted human hearts and endomyocardial biopsies; high-glucose treatment of AC16 cells\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple detection methods (IF, WB, PCR) in human tissue and cell line, but no functional transport assay in cardiomyocytes; single lab\",\n      \"pmids\": [\"36096423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SGLT2 expression is increased and colocalizes with decreased synaptopodin in podocytes of lupus nephritis patients and MRL/lpr mice; CRISPR/Cas9-generated SGLT2 knockout podocyte cells show that SGLT2 mediates mTORC1 activity, and empagliflozin attenuates podocyte injury by reducing mTORC1 activity and enhancing autophagy.\",\n      \"method\": \"CRISPR/Cas9 SGLT2 knockout podocyte cell line; empagliflozin treatment of MRL/lpr mice; immunofluorescence colocalization; mTORC1 activity assays\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR knockout cell line with mechanistic follow-up plus in vivo mouse model; single lab\",\n      \"pmids\": [\"37487609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SGLT2 inhibitor treatment broadly downregulates the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acid transporters) in the proximal tubule; mouse and human SGLT2 interactome studies revealed binding partners consistent with this coordinated transport regulation.\",\n      \"method\": \"Proteomics, phosphoproteomics, metabolomics of kidneys/heart/liver/adipose in nondiabetic and diabetic mice after 1 week SGLT2i; SGLT2 interactome studies in mouse and human tissue\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-omic approach with interactome data; breadth of findings is strong but interactome details are not individually validated by orthogonal methods in the abstract\",\n      \"pmids\": [\"38152989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SGLT2 is expressed at mRNA and protein levels in the proximal tubule; single-cell RNA sequencing of human kidney biopsies confirms SGLT2 expression exclusively in the proximal tubular cell cluster, and SGLT2 inhibitor treatment suppresses mTORC1 signaling across nephron segments, with decreased phospho-S6 protein in both proximal and distal tubules confirmed by immunostaining.\",\n      \"method\": \"Single-cell RNA sequencing of research kidney biopsies from youth-onset T2D patients and healthy controls; phospho-S6 immunostaining; comparison of SGLT2i-treated vs. untreated T2D patients\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — scRNA-seq plus protein-level validation (phospho-S6 IHC) in human biopsy samples; single study, no in vitro mechanistic reconstitution\",\n      \"pmids\": [\"36637914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"COVID-19 proinflammatory cytokines (IL-1β, IL-6, TNF-α) induce redox-sensitive SGLT2 upregulation in endothelial cells, which in turn drives endothelial dysfunction, senescence, NF-κB activation, platelet adhesion/aggregation, and thrombin generation; neutralizing antibodies against these cytokines and empagliflozin both blocked this pathway.\",\n      \"method\": \"Porcine coronary artery endothelial cells incubated with COVID-19 patient plasma; Western blot, immunofluorescence, RT-qPCR; dihydroethidium for oxidative stress; neutralizing antibody blockade; empagliflozin treatment; platelet adhesion/aggregation and thrombin generation assays\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods with cytokine neutralization controls establishing pathway direction; single lab, ex vivo/in vitro model\",\n      \"pmids\": [\"37797691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A novel compound heterozygous mutation (p.W172R; p.P514S) in SLC5A2 is associated with familial renal glucosuria, extending the catalog of loss-of-function mutations that disrupt SGLT2-mediated glucose reabsorption.\",\n      \"method\": \"SLC5A2 gene sequencing; in silico functional prediction tools; literature review of 86 SLC5A2 mutations\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — human genetic association with phenotype, no in vitro transport reconstitution or functional validation of the specific mutations\",\n      \"pmids\": [\"30942416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SGLT2 inhibitor dapagliflozin targets estrogen-related receptor α (ERRα), activating the ERRα–OAT1 axis to enhance uric acid excretion and reduce tubulointerstitial fibrosis in hyperuricemic nephropathy; dual-luciferase reporter assays confirmed transcription factor binding, and ERRα knockin mice showed UA resistance.\",\n      \"method\": \"Transcriptomic analysis of patients and HN mice; HK-2 cell UA stimulation; ERRα knockin mice; ERRα-overexpressed HK-2 cells; dual-luciferase reporter assay; ERRα inhibition; dapagliflozin treatment in vivo and in vitro\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomics plus gain/loss-of-function genetics plus luciferase reporter; single lab, novel pathway identification\",\n      \"pmids\": [\"39168099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MicroRNA-296-5p directly targets and downregulates SGLT2 in lung cancer cells; siRNA knockdown of SGLT2 inhibited cell proliferation and impeded cell cycle progression, establishing SGLT2 as functionally required for lung cancer cell growth.\",\n      \"method\": \"RT-qPCR and Western blot in human lung cancer samples and cell lines; miR-296-5p overexpression; siRNA SGLT2 knockdown; proliferation and cell cycle assays\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — siRNA knockdown with functional readout plus miRNA targeting experiment; single lab\",\n      \"pmids\": [\"30365049\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLC5A2/SGLT2 is an electrogenic sodium-glucose cotransporter expressed predominantly in the S1 segment of the renal proximal tubule, where it mediates the majority of filtered glucose reabsorption coupled to sodium transport; loss-of-function mutations in SLC5A2 cause familial renal glucosuria, and genetic deletion in mice produces massive glucosuria with preserved β-cell function; beyond the kidney, SGLT2 is functionally expressed in pancreatic α-cells (where it regulates glucagon secretion), in cardiomyocytes (where its expression is upregulated by high glucose), in certain cancer cells (where it mediates glucose uptake supporting proliferation), and in endothelial cells (where proinflammatory cytokines upregulate it to drive dysfunction); SGLT2 also traffics aminoglycosides in proximal tubule cells and, through interactome studies, coordinates a broad apical transport complex; pharmacological SGLT2 inhibition suppresses mTORC1 signaling, modulates epigenetic marks via TET2, influences urate excretion through a URAT1-dependent luminal glucose mechanism, and activates ERRα–OAT1 signaling, collectively contributing to renal and cardiovascular protection.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SLC5A2 (SGLT2) is the dominant electrogenic sodium-coupled glucose cotransporter of the renal proximal tubule, where it carries out the bulk of filtered glucose reabsorption: genetic deletion in mice produces ~500-fold glucosuria with preserved pancreatic β-cell function [#1], and single-cell profiling localizes its expression exclusively to the proximal tubular cell cluster [#11]. Loss-of-function mutations across the SLC5A2 coding sequence cause familial renal glucosuria, with the K321R substitution in the eighth transmembrane domain marking a region critical for transport and homozygous lesions producing massive glucosuria accompanied by renal sodium wasting and renin-angiotensin-aldosterone activation, confirming that glucose reabsorption is sodium-coupled in vivo [#2, #3]. Beyond glucose, SGLT2 transports aminoglycosides into proximal tubule cells, accounting for their cellular uptake and cytotoxicity [#0], and it coordinates a broad apical uptake transport network whose components are downregulated upon SGLT2 inhibition [#10]. Pharmacological SGLT2 blockade enhances fractional urate excretion through a URAT1-dependent luminal-glucose mechanism [#4] and via activation of an ERRα–OAT1 axis [#14], and suppresses mTORC1 signaling across nephron segments [#11]. Outside the kidney, SGLT2 is functionally expressed in pancreatic α-cells where its inhibition stimulates glucose-dependent glucagon secretion [#5], in cardiomyocytes where high glucose upregulates it and drives TET2-mediated promoter demethylation of NF-κB and SOD2 [#7, #8], in cytokine-stimulated endothelial cells where it propagates dysfunction and thrombotic signaling [#12], and in breast and lung cancer cells where it supports proliferation [#6, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing which protein regions are essential for human glucose transport, a homozygous missense mutation pinpointed the eighth transmembrane domain as critical for SGLT2 function.\",\n      \"evidence\": \"SLC5A2 coding sequencing and haplotype analysis in consanguineous familial renal glucosuria families\",\n      \"pmids\": [\"15610225\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro reconstitution of the K321R transport defect\", \"Does not quantify residual transport activity\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"By characterizing multiple loss-of-function alleles together with their physiological phenotypes, this work demonstrated that SGLT2-mediated glucose reabsorption is coupled to sodium reabsorption in vivo.\",\n      \"evidence\": \"SLC5A2 sequencing plus plasma renin/aldosterone phenotyping in familial renal glucosuria families\",\n      \"pmids\": [\"16518345\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro transport reconstitution of the mutant alleles\", \"Sodium coupling inferred from RAAS activation rather than direct flux measurement\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Whether SGLT2 is the principal renal glucose-reabsorption pathway and whether its loss is metabolically tolerated was resolved by genetic deletion, which caused massive glucosuria yet preserved β-cell function.\",\n      \"evidence\": \"SGLT2 knockout mouse with metabolic cages, glucose tolerance tests, clamps, and islet perifusion\",\n      \"pmids\": [\"21357472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address extrarenal SGLT2 functions\", \"Mechanism of β-cell mass increase not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Beyond glucose, SGLT2 was shown to be a route for proximal tubule uptake of aminoglycosides, explaining a cellular basis for their nephrotoxicity.\",\n      \"evidence\": \"Competitive uptake assays, phlorizin inhibition, transfection gain-of-function, siRNA knockdown, and Sglt2-null mice\",\n      \"pmids\": [\"25268124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transport stoichiometry for aminoglycosides not determined\", \"Generalizability to other aminoglycosides beyond gentamicin not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The mechanism by which SGLT2 inhibition affects urate handling was mapped to luminal glucose delivery acting through URAT1 rather than tubular GLUT9.\",\n      \"evidence\": \"Canagliflozin treatment plus Sglt2-, Sglt1-, Urat1-, and tubule-specific Glut9-knockout mice with renal clearance studies\",\n      \"pmids\": [\"30427222\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between luminal glucose and URAT1 activity not resolved\", \"Human relevance not directly tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extending SGLT2 function beyond kidney, expression and inhibitor-sensitive proliferation were demonstrated in breast cancer cells, implicating SGLT2 in supporting tumor cell growth.\",\n      \"evidence\": \"RT-PCR, IHC, BrdU assay, siRNA knockdown rescue, and patch-clamp in MCF-7 cells\",\n      \"pmids\": [\"31776304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line, single lab\", \"In vivo tumor relevance not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The basis for SGLT2-inhibitor effects on glucagon was established by localizing SGLT2 to pancreatic α-cells and linking expression heterogeneity to glucagon-secretion responses.\",\n      \"evidence\": \"RNA-seq of 207 donors, validated antibody immunofluorescence, and glucagon secretion assays from human islets\",\n      \"pmids\": [\"31896553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transport mechanism within α-cells not defined\", \"Signaling pathway from SGLT2 to glucagon release not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Whether SGLT2 is expressed in human heart was addressed by detecting it in cardiomyocytes with upregulation in diabetic failing hearts and by high glucose.\",\n      \"evidence\": \"IHC, immunofluorescence, Western blot, and RT-qPCR on human hearts and AC16 cardiomyocytes\",\n      \"pmids\": [\"36096423\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional glucose transport assay in cardiomyocytes\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connecting renal SGLT2 to a growth/stress signaling node, inhibition was shown to suppress mTORC1 signaling across nephron segments.\",\n      \"evidence\": \"scRNA-seq of human kidney biopsies plus phospho-S6 immunostaining in SGLT2i-treated versus untreated T2D patients\",\n      \"pmids\": [\"36637914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanistic link from transport activity to mTORC1 not reconstituted\", \"Distal-tubule effect (lacking SGLT2) implies indirect mechanism\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A cardiac epigenetic role was defined by showing SGLT2 is required for high-glucose-induced TET2-mediated demethylation of NF-κB and SOD2 promoters.\",\n      \"evidence\": \"AC16 high-glucose model with siRNA silencing, pyrosequencing methylation, and ChIP-qPCR for TET2\",\n      \"pmids\": [\"36732760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking SGLT2 transport to TET2 recruitment unknown\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"An endothelial inflammatory circuit was established in which proinflammatory cytokines drive redox-sensitive SGLT2 upregulation that propagates endothelial dysfunction and thrombotic signaling.\",\n      \"evidence\": \"Porcine coronary endothelial cells with COVID-19 plasma, cytokine neutralization, empagliflozin, and platelet/thrombin assays\",\n      \"pmids\": [\"37797691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transport function in endothelium not measured\", \"Ex vivo/in vitro model only\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A podocyte role was demonstrated by showing SGLT2 mediates mTORC1 activity and that its inhibition attenuates podocyte injury in lupus nephritis.\",\n      \"evidence\": \"CRISPR/Cas9 SGLT2-knockout podocyte line plus empagliflozin in MRL/lpr mice with mTORC1 assays\",\n      \"pmids\": [\"37487609\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Coupling between glucose transport and mTORC1 in podocytes not mechanistically defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Multi-omic profiling revealed that SGLT2 inhibition broadly downregulates the proximal-tubule apical transport machinery and identified an SGLT2 interactome consistent with coordinated transport regulation.\",\n      \"evidence\": \"Proteomics, phosphoproteomics, metabolomics, and SGLT2 interactome studies in mouse and human tissue\",\n      \"pmids\": [\"38152989\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Individual interactome partners not orthogonally validated\", \"Direct versus indirect transporter downregulation not distinguished\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A transcriptional target was identified by showing dapagliflozin activates an ERRα–OAT1 axis to enhance urate excretion and reduce fibrosis.\",\n      \"evidence\": \"Transcriptomics, ERRα knockin mice, ERRα-overexpressing HK-2 cells, and dual-luciferase reporter assays\",\n      \"pmids\": [\"39168099\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ERRα effect is independent of glucose transport unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Lung cancer dependency was established by showing miR-296-5p represses SGLT2 and that SGLT2 is functionally required for proliferation and cell-cycle progression.\",\n      \"evidence\": \"RT-qPCR/Western blot in lung cancer samples, miR-296-5p overexpression, siRNA knockdown, and proliferation/cell-cycle assays\",\n      \"pmids\": [\"30365049\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo tumor relevance not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SGLT2 transport activity is mechanistically coupled to its extrarenal signaling effects (mTORC1 suppression, TET2-dependent demethylation, ERRα activation) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking transport to signaling outputs\", \"Direct versus inhibitor-pleiotropic mechanisms not separated\", \"Interactome partners not individually validated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"URAT1\", \"SLC2A9\", \"ESRRA\", \"OAT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":5,"faith_total":5,"faith_pct":100.0}}